What is Proteon?
Proteon operates as a specialized technology firm with a deep-rooted focus on the Plone content management system. Since 2005, the company has distinguished itself by managing the entire lifecycle of Plone applications, from version 2.1 through modern iterations. Their unique value proposition lies in their dual-competency: they possess both the granular knowledge required for custom Plone development and the architectural expertise to manage robust, multi-client server infrastructures. This dual-threat capability allows Proteon to offer comprehensive solutions including versioning, staging, caching, and fail-over management, alongside complex Single Sign-On implementations. By serving as both a developer and a hosting provider, Proteon maintains a unique vantage point in the market, enabling them to solve critical infrastructure problems that standard development shops often struggle to address.
How much funding has Proteon raised?
Proteon has raised a total of $122.2M across 4 funding rounds:
Series A
$12M
Series B
$50M
Unspecified
$15.2M
Series D
$45M
Series A (2007): $12M with participation from Bessemer Venture Partners, Intersouth Partners, TVM Capital, and Devon Park BioVentures
Series B (2009): $50M led by Devon Park BioVentures, MPM Bio IV NVS Strategic Fund, Bessemer Venture Partners, Intersouth Partners, and TVM Capital
Unspecified (2011): $15.2M, investors not publicly disclosed
Series D (2014): $45M featuring Pharmstandard, Deerfield, Bessemer Venture Partners, Intersouth Partners, TVM Capital, MPM Capital, Devon Park BioVentures, Abingworth, and Inbio Ventures
Key Investors in Proteon
Bessemer Venture Partners
Bessemer Venture Partners is a long-standing venture capital firm with a global footprint, established in 1911, that focuses on scaling innovative technology companies.
TVM Capital
TVM Capital Life Science is a transatlantic venture capital firm that provides capital and expertise to support the development of breakthrough therapies and medical products.
Deerfield
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy, supporting companies across the healthcare ecosystem.
What's next for Proteon?
With the support of its latest strategic investment, Proteon is well-positioned to expand its footprint in the enterprise software market. The company is expected to leverage this capital to further refine its infrastructure-as-a-service offerings and potentially scale its proprietary management tools to support larger, more diverse client portfolios. As the demand for secure, scalable, and highly available content management systems continues to rise, Proteon's focus on deep technical integration and reliable hosting will likely remain a core driver of its long-term growth. The firm's ability to navigate complex technical debt and legacy system migrations provides a significant competitive moat, ensuring that it remains a preferred partner for organizations requiring high-performance Plone environments.
See full Proteon company page
